One dose to reduce the new crown

Today, Regeneron announced that its new crown neutralizing antibody combination therapy REGEN-COV (casirivimab+imdevimab) has reached the primary clinical endpoint in a phase 3 clinical trial for the prevention of new crown infection.

In the phase 3 clinical trial called 2069A, a total of 1,505 volunteers who were not infected by the new crown virus participated in the trial.

The results of the trial showed that a single dose of REGEN-COV reduced the participants' risk of developing symptomatic COVID-19 by 81% (p<0.

In a clinical trial called 2069B, 204 COVID-19 patients who tested positive for the new coronavirus but did not show symptoms received a dose of REGEN-COV or a placebo.

The results of the trial showed that a dose of REGEN-COV treatment reduced the risk of turning these asymptomatic patients into symptomatic COVID-19 patients by 31%, reaching the primary endpoint of the trial.

Note: The original text has been deleted

Reference materials:

[1] PHASE 3 PREVENTION TRIAL SHOWED 81% REDUCED RISK OF SYMPTOMATIC SARS-COV-2 INFECTIONS WITH SUBCUTANEOUS ADMINISTRATION OF REGEN-COV™ (CASIRIVIMAB WITH IMDEVIMAB).

▽ attention [drug Mingkang Germany ] micro-channel public number